Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).

Kwee Yong,Marquita Camilleri,William Wilson,Karthink Ramasamy,Matthew Streetly,Jonathan Sive,Ceri Bygrave,Michael A. Chapman,Ruth M de Tute,Selina J Chavda,Elizabeth H. Phillips,Maria Cuadrado,Gavin Pang,Richard G. Jenner,Tushhar Dadaga,Sumaiya Kamora,James D. Cavenagh,Laura Clifton-Hadley,Roger G. Owen,Rakesh Popat

Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).

2021

8000Background: Upfront ASCT for NDTE MM remains under evaluation with high MRD rates following novel induction and consolidation (cons) strategies. Current phase 3 trials support ASCT, however the...

Keywords:

Medicine
Internal medicine
Cyclophosphamide/Dexamethasone
Oncology
Carfilzomib
newly diagnosed
Autologous stem-cell transplantation
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations